A four-dimension deal review is a weekly pipeline review built around buyer readiness instead of rep activity. For every live deal, the team rates four dimensions, problem conviction, evaluation clarity, outcome confidence, and organizational readiness, on a red/yellow/green scale, then acts on the weakest one. A deal moves at the speed of its weakest link, so the practice surfaces stalls early.

Proactive sales opportunities win at 33 to 41 percent, while reactive opportunities win at only 18 to 25 percent (Emblaze, 2025), roughly double the win rate for the same product and effort. The gap exists because reactive sellers enter after the buyer has already defined the problem and evaluation criteria, while proactive sellers shape that thinking before the buyer is in-market. Since 69 to 83 percent of B2B opportunities are reactive, most pipelines are anchored to the lower win rate without leaders realizing it.

Demo enthusiasm and post-demo silence are not contradictions. They are the predictable shape of a buyer who has cleared one confidence gate and not the other. The diagnostic, the second question, and the CRM column that replaces deal stage as the predictor of close.

Some B2B deals stall even when the buyer has every reference and a CFO-approved ROI model. The blocker is not price or information. It is outcome uncertainty, the buyer's silent question: if this fails, what happens to me? Here is how to surface that question and resolve it with the Proof Protocol.

AI-featured B2B purchases double the buying committee and rewrite how it decides while the deal is live. The committee that signs is not the one you pitched. Most sellers still work the week-one map. Organizational Readiness measures whether the seller noticed the room change, and whether the group can still decide.

B2B deals end in "no decision" when a qualified buyer stalls instead of choosing you or a competitor. It is the single largest category of pipeline loss, 40 to 60 percent of qualified deals. The cause is rarely sales execution. It is unmeasured buyer readiness: the buyer was never ready to decide, and nobody scored it.

MEDDIC, BANT, Challenger, and SPIN all instrument the same layer: the deal and the seller. Your no-decision losses come from the layer beneath them, the buyer's decision state, which none of those frameworks measure. DecisionScope is that diagnostic layer. Not a competing methodology. The instrumentation that makes yours work.

Diagnose a stalled B2B deal by running a four-question diagnostic across four readiness dimensions: Problem Conviction, Evaluation Clarity, Outcome Confidence, Organizational Readiness. Score each dimension 1 or 0. The dimension scoring 1 is the gap killing the deal. Match it to a resolution protocol before sending any follow-up.

Most B2B deals that stall after a successful demo do not die from missing information. They die from missing Outcome Confidence, the buyer's ability to picture herself six months past the purchase using the product successfully. The methodology cannot see this dimension. The dashboard cannot measure it. Here is the diagnosis, and three pipeline moves to surface it before the deal goes silent.

Ninety-six percent of B2B companies are functionally invisible in AI discovery. Fifty-one percent of buyers now start vendor research with an AI chatbot. Sixty-nine percent chose a different vendor based on what the AI told them. The discovery channel your funnel was built for has moved. Here is the diagnosis and the three categories of AI-citation work, in priority order.